drugset
drugset / Trial / NCT02784496

Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

NCT02784496 ↗

Phase 2 Completed 8 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.

Timeline

Start
2016-09-29
Primary completion
2024-01-23
Completion
2024-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule — Oral

Indications

myelofibrosis